Fig. 4From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in SwitzerlandCost-effectiveness acceptability curve for the probabilistic sensitivity analysis. CHF, Swiss francs; CEAC, cost-effectiveness acceptability curve; QALYs, quality-adjusted life years; SoC, standard of care; VN, voretigene neparvovecBack to article page